Atara Biotherapeutics

Investors & Media

Latest News

View Press Release
View All News

Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019
Earnings Release
PDF HTML
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

Report Links

Company Overview

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara’s most advanced T-cell immunotherapy in development, tabelecleucel or tab-cel® (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

Atara is also developing off-the-shelf, allogeneic ATA188 for the potential treatment of multiple sclerosis (MS).

View Board of Directors

Investor & Media Contacts

Investors

John Craighead, PhD
Vice President, Investor Relations & Corporate Communications
T: (650) 410-3012
jcraighead@atarabio.com

Susanna Chau
Director, Investor Relations
T: 650-491-5796
schau@atarabio.com

Media

Kerry Beth Daly
Head, Corporate Communications
T: (805) 696-2289
kdaly@atarabio.com

Transfer Agent

Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879
web.queries@computershare.com